跳转至内容
Merck
CN

C4461

Sigma-Aldrich

硫酸粘杆菌素 硫酸盐

≥19,000 IU/mg

别名:

多粘菌素E

登录查看公司和协议定价

关于此项目

CAS Number:
EC 号:
MDL编号:
UNSPSC代码:
51102829
eCl@ss:
34050906
NACRES:
NA.85
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

表单

powder

质量水平

比活

≥19,000 IU/mg

抗生素抗菌谱

Gram-negative bacteria

作用机制

cell membrane | interferes

储存温度

2-8°C

SMILES字符串

[S](=O)(=O)(O)O.N1[C@H](C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C1=O)CCN)CCN)CC(C)C)CC(C)C)CCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCCCC(CC)C)CCN)[C@H](O)C)CCN)[C@H](O)C

InChI

1S/C53H100N16O13.H2O4S/c1-9-30(6)12-10-11-13-41(72)60-33(14-20-54)48(77)69-43(32(8)71)53(82)65-36(17-23-57)45(74)64-38-19-25-59-52(81)42(31(7)70)68-49(78)37(18-24-58)62-44(73)34(15-21-55)63-50(79)39(26-28(2)3)67-51(80)40(27-29(4)5)66-46(75)35(16-22-56)61-47(38)76;1-5(2,3)4/h28-40,42-43,70-71H,9-27,54-58H2,1-8H3,(H,59,81)(H,60,72)(H,61,76)(H,62,73)(H,63,79)(H,64,74)(H,65,82)(H,66,75)(H,67,80)(H,68,78)(H,69,77);(H2,1,2,3,4)/t30?,31-,32-,33+,34+,35+,36+,37+,38+,39+,40-,42+,43+;/m1./s1

InChI key

ZJIWRHLZXQPFAD-LRYSGCCDSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

化学结构:肽

应用

硫酸粘杆菌素被用于透化细菌细胞膜以及研究甘露糖抗性血凝和某些生物体(如鲍曼不动杆菌 A. baumannii )的抗生素耐药性。 它已被用于研究大鼠肾脏hephrotoxicity毒性 ,以及对铜绿假单胞菌的MIC值、时间杀灭动力学和抗生素后效应(PAE)

生化/生理作用

作用机制:与革兰氏阴性菌细胞质膜上的脂质结合并破坏细胞壁完整性。
抗菌谱: 革兰氏阴性菌。
作用机制:与革兰氏阴性菌细胞质膜上的脂质结合并破坏细胞壁完整性。
抗菌谱: 革兰氏阴性菌。硫酸粘杆菌素的肾重吸收被认为可能涉及到有机阳离子转运蛋白和肽转运蛋白,并且该过程对pH敏感

分析说明

易溶于水,几乎不溶于丙酮和乙醇(96%)

其他说明

保持容器密闭,置于干燥通风处。

象形图

Skull and crossbones

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mehri Haeili et al.
Microbial drug resistance (Larchmont, N.Y.), 24(9), 1271-1276 (2018-03-29)
Colistin is considered a last-hope antibiotic against extensively drug-resistant isolates of Acinetobacter baumannii. Resistance to colistin has been rarely reported for A. baumannii. Genetic alterations in the PmrA-PmrB two-component system and lipid A biosynthesis genes may be associated with colistin
Anna Ebbensgaard et al.
Frontiers in microbiology, 9, 2153-2153 (2018-09-25)
Bacterial resistance to classical antibiotics is emerging worldwide. The number of infections caused by multidrug resistant bacteria is increasing and becoming a serious threat for human health globally. In particular, Gram-negative pathogens including multidrug resistant Escherichia coli are of serious
Candace M Marr et al.
Frontiers in microbiology, 11, 595798-595798 (2020-11-17)
Acinetobacter baumannii is a problematic pathogen due to its common expression of extensive drug resistance (XDR) and ability to survive in the healthcare environment. These characteristics are mediated, in part, by the signal transduction system BfmR/BfmS. We previously demonstrated, in
José María Saugar et al.
Antimicrobial agents and chemotherapy, 50(4), 1251-1256 (2006-03-30)
Acinetobacter baumannii has successfully developed resistance against all common antibiotics, including colistin (polymyxin E), the last universally active drug against this pathogen. The possible widespread distribution of colistin-resistant A. baumannii strains may create an alarming clinical situation. In a previous
Deepesh Nagarajan et al.
Science advances, 5(7), eaax1946-eaax1946 (2019-07-30)
Drug resistance is a public health concern that threatens to undermine decades of medical progress. ESKAPE pathogens cause most nosocomial infections, and are frequently resistant to carbapenem antibiotics, usually leaving tigecycline and colistin as the last treatment options. However, increasing

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持